The Hyderabad-based drugmaker had agreed to acquire Lannett in July 2025 for $250 million as part of its strategy to strengthen its presence in the US generics market.
Aurobindo Pharma has successfully cleared a significant US regulatory hurdle concerning its $250 million acquisition of Lannett. This strategic move, initially agreed upon in July 2025, is aimed at substantially strengthening the Hyderabad-based drugmaker's position in the…
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.